S126: GEMTUZUMAB-BASED INDUCTION CHEMOTHERAPY COMBINED WITH MIDOSTAURIN FOR FLT3 MUTATED AML. RESULTS FROM THE NCRI AML19 "MIDOTARG" PILOT TRIAL. (23rd June 2022) - Russell, N.; Wilhelm-Benartzi, C.; Othman, J.; Dillon, R.; Potter, N.; Jovanovic, J.; Gilkes, A.; Batten, L. M.; Canham, J.; Hinson, E. L.; Kottaridis, P.; Cavenagh, J.; et al.